BioPharma Resources

Therapeutic area

Cardiovascular and metabolic

Heart failure, lipids, hypertension, diabetes and obesity. Drugs are placed in areas by keyword matches on their FDA pharmacologic class and approved use, and trials by their listed conditions, so a few land in the wrong area.

Last checked: Nov 19, 2026Source: Drugs@FDA, ClinicalTrials.govMethods & limitations

Approvals since 2023

33

Originals, plus breakthrough or accelerated new uses

Recruiting Phase 2

168

Industry-sponsored

Recruiting Phase 3

192

Industry-sponsored

Recruiting Phase 4 (post-approval)

28

Industry-sponsored

Recent approvals

All
  • Sunharbo (Asundexian) · Bayer Healthcare NovelPriority reviewNov 9, 2026

    To reduce the risk of stroke in adults following a recent mild-to-moderate non-cardioembolic ischemic stroke or a high-risk transient ischemic attack

  • Onswik (Insulin Efsitora Alfa-Gobe) · Eli Lilly and CO NovelSep 23, 2026

    To improve glycemic control in adults with type 2 diabetes mellitus, as an adjunct to diet and exercise

  • Garzulys (Insulin Aspart-Fsan) · Emerge Bioscience Pte. Ltd. Sep 15, 2026
  • Garzulys (Insulin Aspart-Fsan) · Emerge Bioscience Pte. Ltd. Jul 24, 2026
  • Lipfendra (Enlicitide Decanoate) · Msd NovelPriority reviewJul 15, 2026

    To reduce low-density lipoprotein cholesterol

  • Baxfendy (Baxdrostat) · Astrazeneca Ab NovelPriority reviewMay 15, 2026

    To treat hypertension in combination with other antihypertensive drugs

  • Langlara (Insulin Glargine-Aldy) · Sunshine Lake Pharma CO LTD Apr 29, 2026
  • Foundayo (Orforglipron Calcium) · Eli Lilly and CO NovelApr 1, 2026

    To reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition, in combination with a reduced-calorie diet and increased physical activity

  • Awiqli Flextouch (Insulin Icodec) · Novo Nordisk INC NovelOrphanMar 26, 2026
  • Yartemlea (Narsoplimab-Wuug) · Omeros Corp NovelBreakthrough therapyPriority reviewOrphanDec 23, 2025

    To treat hematopoietic stem cell transplant-associated thrombotic microangiopathy

  • Myqorzo (Aficamten) · Cytokinetics NovelBreakthrough therapyOrphanDec 19, 2025

    To treat symptomatic obstructive hypertrophic cardiomyopathy

  • Cardamyst (Etripamil) · Milestone Pharms USA NovelDec 12, 2025

    To treat episodes of paroxysmal supraventricular tachycardia

  • Lerochol (Lerodalcibep-Liga) · Lib Therapeutics, Inc. NovelDec 12, 2025

    To reduce low-density lipoprotein cholesterol in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia, as an adjunct to diet and exercise

  • Redemplo (Plozasiran Sodium) · Arrowhead NovelBreakthrough therapyOrphanNov 18, 2025

    To reduce triglycerides in adults with familial chylomicronemia syndrome

  • Evkeeza (Evinacumab-Dgnb) · Regeneron Pharmaceuticals Breakthrough therapyPriority reviewOrphanSep 25, 2025

Recruiting trials by phase

Industry-sponsored drug and biologic trials.

Most approvals since then, by company

Drugs in development

Investigational drugs in Phase 2 and 3 trials for conditions in this area, most trials first.

All
  • CagrilintidePhase 320 trials

    Novo Nordisk · Obesity, Overweight, Type 2 Diabetes

  • BerobenatidePF-08653944, MET097Phase 319 trials

    Pfizer · Obesity, Overweight and/or Obesity, Overweight

  • IanalumabVAY736, VAY736 AIPhase 318 trials

    Novartis · Primary Immune Thrombocytopenia (ITP), Systemic Lupus Erythematosus, Sjogren Syndrome

  • RetatrutideLY3437943Phase 316 trials

    Eli Lilly · Obesity, Overweight, Type 2 Diabetes

  • Maridebart cafraglutideAMG 133Phase 314 trials

    Amgen · Obesity, Overweight, Obstructive Sleep Apnea

  • EloralintideLY3841136Phase 313 trials

    Eli Lilly · Obesity, Overweight, Diabetes Mellitus, Type 2

  • HRS9531Phase 313 trials

    Fujian Shengdi Pharmaceutical Co., Ltd. · Type 2 Diabetes, Chronic Management of Body Weight, Metabolic Dysfunction-Associated Steatohepatitis (MASH)

  • NNC0487-0111Phase 312 trials

    Novo Nordisk · Obesity, Overweight, Obstructive Sleep Apnoea

  • REGN7508CenvacibartPhase 312 trials

    Regeneron · Atrial Fibrillation (AF), Venous Thromboembolism (VTE), Venous Thromboembolism

  • BofanglutideGZR18, BofanglutidaPhase 311 trials

    Gan & Lee Pharmaceuticals. · Type 2 Diabetes Mellitus (T2DM), Obstructive Sleep Apnea (OSA), Obesity/Overweight in Adult

  • HRS-7535Phase 310 trials

    Shandong Suncadia Medicine Co., Ltd. · Type 2 Diabetes, Chronic Kidney Disease, Adults With Heart Failure, Mild Decrease in Ejection Fraction/Preserved Ejection Fraction, and Obesity

  • UBT251Phase 310 trials

    The United Bio-Technology (Hengqin) Co., Ltd. · Obesity, Obesity &Amp; Overweight, Diabetes Mellitus, Type 2

  • ElecoglipronPhase 39 trials

    AstraZeneca · Type 2 Diabetes Mellitus, Obesity, Overweight

  • FrexalimabSAR441344Phase 39 trials

    Sanofi · Multiple Sclerosis, Focal Segmental Glomerulosclerosis, Glomerulonephritis Minimal Lesion

  • LenbelintideAZD6234Phase 39 trials

    AstraZeneca · Obesity or Overweight, Obesity, Overweight

Largest recruiting Phase 3 trials

All

More: Cardiovascular and metabolic news · literature

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.